Cara Therapeutics, Inc. (NASDAQ:CARA) Receives Average Rating of “Hold” from Brokerages

Shares of Cara Therapeutics, Inc. (NASDAQ:CARA) have received an average recommendation of “Hold” from the five ratings firms that are currently covering the company, MarketBeat reports. Five equities research analysts have rated the stock with a hold recommendation. The average twelve-month price target among brokerages that have covered the stock in the last year is $27.84.

Separately, StockNews.com assumed coverage on shares of Cara Therapeutics in a report on Wednesday, January 8th. They issued a “sell” rating on the stock.

Institutional Trading of Cara Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. XTX Topco Ltd purchased a new position in Cara Therapeutics during the 3rd quarter valued at $29,000. FMR LLC boosted its stake in shares of Cara Therapeutics by 18.5% during the 3rd quarter. FMR LLC now owns 210,312 shares of the biopharmaceutical company’s stock valued at $65,000 after purchasing an additional 32,789 shares in the last quarter. Finally, Disciplined Growth Investors Inc. MN increased its position in shares of Cara Therapeutics by 6.6% during the second quarter. Disciplined Growth Investors Inc. MN now owns 1,935,718 shares of the biopharmaceutical company’s stock valued at $499,000 after buying an additional 120,660 shares during the period. Hedge funds and other institutional investors own 44.66% of the company’s stock.

Cara Therapeutics Stock Performance

Shares of Cara Therapeutics stock opened at $5.06 on Friday. Cara Therapeutics has a 52-week low of $2.71 and a 52-week high of $13.80. The company’s 50 day moving average price is $4.21 and its 200-day moving average price is $3.92. The stock has a market capitalization of $23.12 million, a price-to-earnings ratio of -0.24 and a beta of 0.51.

Cara Therapeutics Company Profile

Cara Therapeutics, Inc, a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis.